Company Encyclopedia
View More
name
BLUE SAIL MEDICAL
002382.SZ
Blue Sail Medical Co.,Ltd. engages in the health protection, medical device, and nursing businesses in China and internationally. The company operates through Health Protection Division; Cardiovascular and Cerebrovascular Department; and Emergency Rescue Division segments. The company involved in cardiovascular and cerebrovascular business with stents, balloons, and heart valves.
345.63 B
002382.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care SuppliesIndustry
Industry Ranking39/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-6.12%D
    • Profit Margin-8.85%D
    • Gross Margin17.19%D
  • Growth ScoreD
    • Revenue YoY-3.61%D
    • Net Profit YoY-18.31%D
    • Total Assets YoY-3.09%D
    • Net Assets YoY-2.64%D
  • Cash ScoreD
    • Cash Flow Margin-1129.57%E
    • OCF YoY-3.61%D
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreC
    • Gearing Ratio41.01%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BLUE SAIL MEDICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 286 million yuan

    According to the Zhitong Finance APP, BLUE SAIL MEDICAL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 4.182 billion yuan, a year-on-year decrease of 10.15%. The net loss attributable to shareholders of the listed company was 286 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 364 million yuan. The basic loss per share was 0.28 yuan

    Zhitong·
    SZ
    002382
    +0.55%
    Zhitong·
    SZ
    002382
    +0.55%

    BLUE SAIL MEDICAL released its performance for the first half of the year, with a net loss attributable to the parent company of 135 million yuan, narrowing by 15.88%

    According to the Zhitong Finance APP, BLUE SAIL MEDICAL released its semi-annual report for 2025, showing an operating income of 2.781 billion yuan, a year-on-year decrease of 7.49%. The net loss attributable to shareholders of the listed company was 135 million yuan, a year-on-year narrowing of 15.88%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 210 million yuan, a year-on-year increase of 11.82%. The basic loss per share was 0.13 yuan

    Zhitong·
    SZ
    002382
    +0.55%
    Zhitong·
    SZ
    002382
    +0.55%

    BLUE SAIL MEDICAL: Subsidiary obtains credit line of 100 million, disclosure of guarantee progress and situation

    BLUE SAIL MEDICAL announced that its subsidiary Shandong Blue Sail New Materials applied for a credit line of no more than 100 million from CZBANK, with good progress on the guarantee. In 2024, the company and its subsidiaries plan to apply for a comprehensive credit line of no more than 1.71 billion. The subsidiary's debt-to-asset ratio is 63.12%, and after the new guarantee, the guarantee balance is 385 million, with a remaining available limit of 949 million. The financial performance of the guaranteed party is poor, but there are no adverse guarantee situations

    Zhitong·
    SH
    601916
    -0.97%
    HK
    02016
    -0.38%
    SZ
    002382
    +0.55%
    Zhitong·
    SH
    601916
    -0.97%
    HK
    02016
    -0.38%
    SZ
    002382
    +0.55%

    BLUE SAIL MEDICAL expects to trigger the condition for the downward adjustment of the conversion price of "BLUE SAIL Convertible Bonds"

    BLUE SAIL MEDICAL announced that it is expected to trigger the condition for the downward adjustment of the conversion price of "BLUE SAIL Convertible Bonds." As of July 21, 2025, the company's stock has closed below the conversion price of RMB 12.00 per share for 85% of the 10 trading days. If triggered, the company will convene a board meeting to review whether to make the adjustment and will disclose the information in a timely manner. The current conversion period is from December 3, 2020, to May 27, 2026, and the latest conversion price was adjusted to RMB 12.00 per share on July 8, 2025

    Zhitong·
    SZ
    002382
    +0.55%
    Zhitong·
    SZ
    002382
    +0.55%

    BLUE SAIL MEDICAL's subsidiary's next-generation recyclable transcatheter aortic valve replacement delivery system has obtained CE certification

    According to the Zhitong Finance APP, BLUE SAIL MEDICAL announced that its subsidiary, NVTGmbH in the cardiovascular division, has developed a new generation of recyclable transcatheter aortic valve replacement (TAVR) delivery system IMPERIA™ (referred to as "IMPERIA™ delivery system"), which has obtained CE certification from the European Union. This delivery system is used in conjunction with the company's already listed ALLEGRA™ series aortic valves to achieve recyclable functionality

    Zhitong·
    SZ
    002382
    +0.55%
    Zhitong·
    SZ
    002382
    +0.55%
    © 2025 Longbridge｜Disclaimer